JP7840327B2 - 新規インダゾールアセチレン誘導体 - Google Patents

新規インダゾールアセチレン誘導体

Info

Publication number
JP7840327B2
JP7840327B2 JP2023527318A JP2023527318A JP7840327B2 JP 7840327 B2 JP7840327 B2 JP 7840327B2 JP 2023527318 A JP2023527318 A JP 2023527318A JP 2023527318 A JP2023527318 A JP 2023527318A JP 7840327 B2 JP7840327 B2 JP 7840327B2
Authority
JP
Japan
Prior art keywords
methyl
indazol
imidazol
thiazol
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023527318A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023550902A5 (https=
JP2023550902A (ja
JPWO2022117477A5 (https=
Inventor
コジモ ドレンテ，
アニック ゴアグラー，
デーヴィッド スティーブン ヘウィングス，
ゲオルク ジェスキー，
ザンダー， ウルリーケ オブスト
アントニオ リッチ，
Original Assignee
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト filed Critical エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト
Publication of JP2023550902A publication Critical patent/JP2023550902A/ja
Publication of JP2023550902A5 publication Critical patent/JP2023550902A5/ja
Publication of JPWO2022117477A5 publication Critical patent/JPWO2022117477A5/ja
Application granted granted Critical
Publication of JP7840327B2 publication Critical patent/JP7840327B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2023527318A 2020-12-01 2021-11-29 新規インダゾールアセチレン誘導体 Active JP7840327B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20210859 2020-12-01
EP20210859.3 2020-12-01
PCT/EP2021/083279 WO2022117477A1 (en) 2020-12-01 2021-11-29 New indazole acetylene derivatives

Publications (4)

Publication Number Publication Date
JP2023550902A JP2023550902A (ja) 2023-12-06
JP2023550902A5 JP2023550902A5 (https=) 2024-12-04
JPWO2022117477A5 JPWO2022117477A5 (https=) 2024-12-04
JP7840327B2 true JP7840327B2 (ja) 2026-04-03

Family

ID=73654642

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023527318A Active JP7840327B2 (ja) 2020-12-01 2021-11-29 新規インダゾールアセチレン誘導体

Country Status (15)

Country Link
US (1) US20240002390A1 (https=)
EP (1) EP4255908A1 (https=)
JP (1) JP7840327B2 (https=)
KR (1) KR20230116799A (https=)
CN (1) CN116490182A (https=)
AR (1) AR124170A1 (https=)
AU (1) AU2021393722A1 (https=)
CA (1) CA3197659A1 (https=)
CL (1) CL2023001440A1 (https=)
CO (1) CO2023006912A2 (https=)
CR (1) CR20230218A (https=)
IL (1) IL303064A (https=)
MX (1) MX2023006176A (https=)
PE (1) PE20240099A1 (https=)
WO (1) WO2022117477A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114008049B (zh) 2019-06-21 2024-07-05 豪夫迈·罗氏有限公司 用于癌症治疗的egfr抑制剂
JP7840324B2 (ja) 2020-12-01 2026-04-03 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 新規インダゾール誘導体
JP2025516543A (ja) * 2022-05-13 2025-05-30 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がんの治療のためのアロステリックおよびオルソステリックｅｇｆｒ阻害剤の組み合わせ

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018522879A (ja) 2015-06-30 2018-08-16 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｅｇｆｒ阻害剤およびその使用方法
WO2018220149A1 (en) 2017-06-02 2018-12-06 F. Hoffmann-La Roche Ag Compounds
WO2020254547A1 (en) 2019-06-21 2020-12-24 F. Hoffmann-La Roche Ag New egfr inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201834651A (zh) * 2016-12-22 2018-10-01 瑞士商赫孚孟拉羅股份公司 化合物
SG11202011818YA (en) * 2018-06-29 2020-12-30 Hoffmann La Roche Compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018522879A (ja) 2015-06-30 2018-08-16 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｅｇｆｒ阻害剤およびその使用方法
WO2018220149A1 (en) 2017-06-02 2018-12-06 F. Hoffmann-La Roche Ag Compounds
WO2020254547A1 (en) 2019-06-21 2020-12-24 F. Hoffmann-La Roche Ag New egfr inhibitors

Also Published As

Publication number Publication date
CN116490182A (zh) 2023-07-25
US20240002390A1 (en) 2024-01-04
PE20240099A1 (es) 2024-01-18
CR20230218A (es) 2023-07-07
CA3197659A1 (en) 2022-06-09
EP4255908A1 (en) 2023-10-11
JP2023550902A (ja) 2023-12-06
WO2022117477A1 (en) 2022-06-09
TW202237611A (zh) 2022-10-01
AR124170A1 (es) 2023-02-22
CL2023001440A1 (es) 2023-12-01
CO2023006912A2 (es) 2023-06-09
MX2023006176A (es) 2023-06-08
AU2021393722A1 (en) 2023-04-13
KR20230116799A (ko) 2023-08-04
IL303064A (en) 2023-07-01

Similar Documents

Publication Publication Date Title
JP7561779B2 (ja) 新規ｅｇｆｒ阻害剤
JP6805220B2 (ja) 治療上活性な化合物およびそれらの使用方法
JP7411588B2 (ja) 化合物
JP7840324B2 (ja) 新規インダゾール誘導体
EP3986895A1 (en) Egfr inhibitors for the treatment of cancer
JP7840327B2 (ja) 新規インダゾールアセチレン誘導体
TW201524953A (zh) 治療活性化合物及其使用方法（二）
US20240408064A1 (en) Ras inhibitors, compositions and methods of use thereof
JP7798887B2 (ja) 新規インダゾール誘導体
KR20250012058A (ko) 신규 이미다졸 유도체
RU2853003C1 (ru) Новые индазолацетиленовые производные
WO2023209090A1 (en) Bicyclic heteroaromatic compounds and their application in the treatment of cancer
TWI915460B (zh) 新穎吲唑乙炔衍生物、製備其之方法、包含其之醫藥組合物及其用途
HK40094041A (zh) 新的吲唑乙炔衍生物
HK40115444A (zh) 新的吲唑衍生物
HK40067220A (zh) 新egfr抑制剂
HK40092553A (zh) 新的吲唑衍生物
HK40092556A (zh) 新的吲唑衍生物
HK1113927B (en) Substituted triazole derivatives as oxytocin antagonists
HK1113927A1 (en) Substituted triazole derivatives as oxytocin antagonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241126

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250617

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251208

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260310

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260324

R150 Certificate of patent or registration of utility model

Ref document number: 7840327

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150